OrphoMed is a clinical stage biotechnology company focused on the development of best-in-class therapies for the treatment of inadequately-controlled gastrointestinal disorders. The company’s strategy is to take molecules that have proven mechanisms of action and to engineer improved pharmacological properties via a proprietary platform technology. OrphoMed’s lead program is aimed at treating irritable bowel syndrome with diarrhea (IBS-D), a seriously debilitating disorder that affects the intestinal tract. IBS-D has no identifiable cause and represents an important unmet medical need.
San Francisco, CA
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.